NICE recommends risdiplam for spinal muscular atrophy

NICE has published draft guidance recommending risdiplam (Evrysdi) as part of a managed access agreement (MAA) for the treatment of the rare genetic disorder spinal muscular atrophy (SMA). - News - PharmaTimes

Related Keywords

Amanda Pritchard ,Elizabeth Wraige , ,Evelina London ,Nice ,